{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338006","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2026-08-06T20:10:59+00:00","discovered_at":"2026-08-06T20:12:01.655740+00:00","generated_at":"2026-08-06T20:14:31.100518+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Definium Therapeutics Q2 net loss $159M; Phase 3 Emerge MDD study meets primary endpoint","bullets":["Phase 3 Emerge in MDD met primary endpoint: 8.1-point MADRS improvement vs placebo at Week 6 (p<0.0001).","Cash, equivalents and investments $1.1B as of June 30, 2026, up from $411.6M at Dec 31, 2025.","Net loss $159.0M for Q2 2026 vs $42.7M in Q2 2025, including $86.2M non-cash warrant liability charge.","R&D expenses $48.7M, G&A $26.4M; completed public offering of $805M gross proceeds.","Topline GAD results from Voyage expected week of Aug 10; Panorama in Sept 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338006","json":"https://secwatch.observer/filing/0001193125-26-338006.json","markdown":"https://secwatch.observer/filing/0001193125-26-338006.md","text":"https://secwatch.observer/filing/0001193125-26-338006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/0001193125-26-338006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:14:31.100518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}